Immunobiochemical analysis of paraoxonase1 (anti-oxidant), xanthine oxidase (oxidant) enzymes and lipid profile of cardiac disease patients in Lahore metropolitan, Pakistan

Journal of Clinical Laboratory Analysis

Volumn 24, Issue 5, 2010, Pages 348-356

  Samra, Zahoor Qadir ^a   Sana, Adeela ^a   Bano, Sadia ^a   Farooq, Mariam ^a   Dar, Nadia ^b   Athar, Muhammad Amin ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

^b Jinnah Degree College for Women   (Pakistan)

Author keywords

Antibodies; Competitive ELISA; Free radicals; Paraoxonase1; Xanthine oxidase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CHOLESTEROL; LIPID PEROXIDE; THIOL; TRIACYLGLYCEROL; XANTHINE OXIDASE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART DISEASE; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATION; PAKISTAN; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ARYLDIALKYLPHOSPHATASE; BLOTTING, WESTERN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART DISEASES; HUMANS; IMMUNOENZYME TECHNIQUES; LIPIDS; MALE; MIDDLE AGED; PAKISTAN; PROGNOSIS; XANTHINE OXIDASE;

EID: 77957262533     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20417     Document Type: Article

References (36)

1. La Du BN. Human serum paraoxonase in pharmacogenetics of drug metabolism. New York: W.Kalow, Pergamon Press, 1992. p 52-91.
2. Lund-Katz S, Liu L, Thuahnai ST, Phillips MC. High density lipoprotein structure. Front Biosci 2003;8:1044-1054.
3. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase gene is a risk factor for coronary artery disease. J Clin Invest 1995;96:3005-3008.
4. Aviram M, Hardak E, Vaya J, Mahmood S. Human serum paraoxonases Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000;101:2510-2517.
5. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598-608.
6. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase polymorphim. Am J Hum Genet 1982;35:1126-1138.
7. Mackness MI, Durrington PN. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;15:243-253.
8. Mackness MI, Bouiller A, Hennuyer N, et al. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun 2000;269:232-236.
9. Mackness B, Mackness MI, Durrington PN, et al. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest 2000;30:4-10.
10. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease. Arterioscler Thromb Vasc Biol 2001;21:1451-1457.
11. McCord JM. Oxygen-derived radicals: A link between reperfusion injury and inflammation. Fed Proc 1987;46:2402-2406.
12. Parks DA, Granger DN, Xanthine oxidase: Biochemistry and physiology. Acta Physiol Scand 1986;548:87-99.
13. Ashraf M, Samra ZQ. Subcellular distribution of xanthine oxidase during cardiac ischemia and reperfusion: An immunocytochemical study. J Submicros Cyt Path 1993;25:193-201.
14. Yokoyama Y, Beckman JS, Beckman TK, et al. Circulating xanthine oxidase: Potential mediator of ischemic injury. Am J Physiol 1990;258:G564-G570.
15. Samra ZQ, Siddique Z. Distibution of xanthine oxidase during calcium paradox conditions of rat heart. Punjab Univ J Zool 1998;13:89-98.
16. Grander TJ, Stewart FR, Casale AS, Downey JM, Chambers DE. Reduction of myocardial ischemic injury with oxygen derived free radical scavengers. Surgery 1993;94:423-427.
17. Kourie JI. Interaction of reactive oxygen species with ion transport mechanisms. Am J Physiol 1988;275:1-24.
18. Cesselli D, Jakoniuk I, Barlucchi L, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001;89:279-286.
19. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-106.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
21. El-Saadani M, Esterbauer H, El-sayed M, Goher M, Nassar AY, Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoprotein using commercially available reagent. J Lipid Res 1989;30:627-630.
22. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 1993;121:257-262.
23. Harlow ED, Lane D. 1988. Antibodies: a laboratory manual. Cold Spring Harbour, NY: Cold Spring Harbour Labs.
24. Walker J. 1994. Methods in molecular biology: Basic protein and peptide protocol, Vol. 32. Totowa, NJ: Humana Press Inc.
25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
26. Towbin HK, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose membrane. Proc Natl Acad Sci 1979;76:4350-4359.
27. Battelli GM, Abbondanza A, Musiani S, et al. Determination of xanthine oxidase in human serum by a competitive enzyme-linked immunosorbent assay. Clin Chim Acta 1999;281:147-158.
28. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem 1976;72:248-251.
29. Halliwell B. Free radicals, antioxidants and human disease: Curiosity, cause or consequences. Lancet 1994;344:721-724.
30. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985;312:159-163.
31. Sumegova K, Blazicek P, Waczulikova I, Zitnanova I, Durackova Z. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks. Acta Biochem Pol 2006;53:783-787. (Pubitemid 46090127)
32. Topçuoglu A, Uzun H, Aydin S, et al. The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. Tohoku J Exp Med 2005;205:79-86.
33. McEleveen J, Mackness MI, Solley CM, Peard T, Warner S, Walker H. Distribution of paraoxon, hydrolyzing activity in the serum of patients after myocardial infarction. Clin Chem 1986;32:671-673.
34. Lee CH, Lee KY, Choe KH, et al. Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer. J Prev Med Pub Health 2005;38:345-350.
35. Pronai L, Ichikawa Y, Nakazawa H, Arimori S. Enhanced superoxide generation and the decreased superoxide scavenging activity of peripheral blood leukocytes in Behcet's disease-effects of colchicines 1991;9:227-233.
36. Aviram M, Rosenblat M, Billecke S. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biol Med 1999;26:892-904.